Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
2,553.40
+47.00 (1.88%)
Jun 29, 2026, 9:50 AM IST
Caplin Point Laboratories Employees
Caplin Point Laboratories had 3,966 employees as of March 31, 2025. The number of employees increased by 560 or 16.44% compared to the previous year.
Employees
3,966
Change (1Y)
560
Growth (1Y)
16.44%
Revenue / Employee
5.51M INR
Profits / Employee
1.62M INR
Market Cap
190.58B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 3,966 | 560 | 16.44% |
| Mar 31, 2024 | 3,406 | 1,764 | 107.43% |
| Mar 31, 2023 | 1,642 | -1,358 | -45.27% |
| Mar 31, 2022 | 3,000 | 1,325 | 79.10% |
| Mar 31, 2021 | 1,675 | -21 | -1.24% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Alembic Pharmaceuticals | 16,571 |
| Akums Drugs and Pharmaceuticals | 7,337 |
| Emcure Pharmaceuticals | 6,731 |
| Piramal Pharma | 5,476 |
| Gland Pharma | 4,351 |
| NATCO Pharma | 4,199 |
| Eris Lifesciences | 3,354 |
| Strides Pharma Science | 3,301 |
Caplin Point Laboratories News
- 19 days ago - Top gainers in morning trade: balaji amines at ₹2,237.30 up 7.00%, ola electric mobility at ₹47.51 up 6.93%, caplin point laboratories at ₹2,216.00 up 4.97% - Business Upturn
- 6 weeks ago - Caplin Point Laboratories Transcript: Q4 25/26 - Transcripts
- 6 weeks ago - Caplin Point Laboratories Slides: Q4 2026 - Filings
- 6 weeks ago - Caplin Point Laboratories Quarterly report: Q4 2026 - Filings
- 7 weeks ago - Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market - Business Upturn
- 3 months ago - Caplin Point receives USFDA approval for potassium phosphates injection - Business Upturn
- 3 months ago - Caplin Point Laboratories arm receives USFDA approval for potassium phosphates injection - Business Upturn
- 4 months ago - Caplin Point subsidiary secures USFDA final approval for Desmopressin Acetate Injection ANDA - Business Upturn